Last $0.0090 USD
Change Today -0.0003 / -3.23%
Volume 67.9K
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

avax technologies inc (AVXT) Snapshot

Open
$0.0085
Previous Close
$0.0093
Day High
$0.0095
Day Low
$0.0085
52 Week High
01/9/14 - $0.05
52 Week Low
12/31/13 - $0.0025
Market Cap
1.3M
Average Volume 10 Days
105.6K
EPS TTM
$-0.04
Shares Outstanding
142.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AVAX TECHNOLOGIES INC (AVXT)

Related News

No related news articles were found.

avax technologies inc (AVXT) Related Businessweek News

No Related Businessweek News Found

avax technologies inc (AVXT) Details

AVAX Technologies, Inc., a development stage biopharmaceutical company, specializes in the development and commercialization of vaccine therapies and other technologies for the treatment of cancer. The company’s autologous cell vaccine immunotherapy products include M-VAX intended for the treatment of melanoma is under phase II clinical trials; and O-VAX intended for the treatment for ovarian cancer is under phase I/II trials. It also provides contract manufacturing and research services. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

9 Employees
Last Reported Date: 05/5/11
Founded in 1990

avax technologies inc (AVXT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

avax technologies inc (AVXT) Key Developments

AVAX Technologies Inc. Announces Expansion of Clinical Study with Autologous Ovarian Cancer Vaccine Ovax

AVAX Technologies Inc. announced that it has expanded its ongoing Phase 1/2 study ("Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients with relapsed Stage III or IV Ovarian Cancer") to include all five Cancer Treatment Centers of America(R) (CTCA) regional hospitals. In addition, clinical data from the study was selected to be presented at the Society of Gynecologic Oncology ("SGO") 19(th) Annual Winter Meeting February 20 -- 22, 2014 at Breckenridge, Colorado. The SGO is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVXT:US $0.01 USD -0.0003

AVXT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVXT.
View Industry Companies
 

Industry Analysis

AVXT

Industry Average

Valuation AVXT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVAX TECHNOLOGIES INC, please visit www.avax-tech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.